Mayne Pharma intros generic Monodox
Adelaide, Australia-based Mayne Pharma is launching its generic Monodox (doxycycline monohydrate) capsules in the United States. The product is indicated to treat various infections, including as an adjunctive therapy for severe acne.
“This launch will further broaden Mayne Pharma’s dermatology portfolio of branded and generic products,” Mayne Pharma CEO Scott Richards said. “Mayne Pharma is committed to helping patients and physicians cost-effectively manage various skin conditions including acne and psoriasis.”
The product had U.S. sales of $30 million for the 12 months ended January 2018. Mayne Pharma’s generic Monodox will be available in 50-, 75- and 100-mg dosage strengths.
“This launch will further broaden Mayne Pharma’s dermatology portfolio of branded and generic products,” Mayne Pharma CEO Scott Richards said. “Mayne Pharma is committed to helping patients and physicians cost-effectively manage various skin conditions including acne and psoriasis.”
The product had U.S. sales of $30 million for the 12 months ended January 2018. Mayne Pharma’s generic Monodox will be available in 50-, 75- and 100-mg dosage strengths.